Assessment of insulin-like growth factor 1 receptor as an oncogene in esophageal squamous cell carcinoma and its potential implication in chemotherapy

Oncology Reports

Volumn 32, Issue 4, 2014, Pages 1601-1609

  Ma, Wang ^a   Zhang, Tengfei ^a   Pan, Jian ^b   Shi, Ni ^c   Fan, Qingxia ^a   Wang, Liuxing ^a   Lu, Shih Hsin ^a,d  

^a ZHENGZHOU UNIVERSITY   (China)

^b CHILDREN S HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^c OHIO STATE UNIVERSITY   (United States)

^d CANCER HOSPITAL   (China)

Author keywords

Chemotherapy response; ESCC; IGF 1R; Oncogene

Indexed keywords

CISPLATIN; FLUOROURACIL; SOMATOMEDIN C RECEPTOR; ANTINEOPLASTIC AGENT; IGF1R PROTEIN, HUMAN; SOMATOMEDIN RECEPTOR;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER TISSUE; CARCINOMA CELL LINE; CELL CYCLE; CELL PROLIFERATION; CLONOGENESIS; COLONY FORMATION; CONTROLLED STUDY; DRUG RESPONSE; DRUG SENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR GROWTH; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; CANCER STAGING; CARCINOMA, SQUAMOUS CELL; COHORT ANALYSIS; DRUG EFFECTS; DRUG SCREENING; ESOPHAGEAL NEOPLASMS; GENETICS; MIDDLE AGED; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; COHORT STUDIES; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; MALE; MICE; MIDDLE AGED; NEOPLASM STAGING; ONCOGENES; RECEPTORS, SOMATOMEDIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84923068390     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3348     Document Type: Article

References (30)

1. Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. He J, Gu D, Wu X, et al: Major causes of death among men and women in China. N Engl J Med 353: 1124-1134, 2005. (Pubitemid 41317435)
3. Stoner GD and Gupta A: Etiology and chemoprevention of esophageal squamous cell carcinoma. Carcinogenesis 22: 1737-1746, 2001. (Pubitemid 33064837)
4. Qi YJ, Chao WX and Chiu JF: An overview of esophageal squamous cell carcinoma proteomics. J Proteomics 75: 3129-3137, 2012.
5. Holmes RS and Vaughan TL: Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol 17: 2-9, 2007. (Pubitemid 44918357)
6. Lin Q, Gao XS, Qiao XY, et al: Phase I trial of escalating-dose cisplatin with 5-fluorouracil and concurrent radiotherapy in Chinese patients with esophageal cancer. Acta Med Okayama 62: 37-44, 2008. (Pubitemid 351463556)
7. Liao Y, Abel U, Grobholz R, et al: Up-regulation of insulin-like growth factor axis components in human primary prostate cancer correlates with tumor grade. Hum Pathol 36: 1186-1196, 2005. (Pubitemid 41540395)
8. Tsuta K, Mimae T, Nitta H, et al: Insulin-like growth factor-1 receptor protein expression and gene copy number alterations in non-small cell lung carcinomas. Hum Pathol 44: 975-982, 2013.
9. Rikhof B, de Jong S, Suurmeijer AJ, Meijer C and van der Graaf WT: The insulin-like growth factor system and sarcomas. J Pathol 217: 469-482, 2009.
10. Ucar DA, Magis AT, He DH, et al: Inhibiting the interaction of cMET and IGF-1R with FAK effectively reduces growth of pancreatic cancer cells in vitro and in vivo. Anticancer Agents Med Chem 13: 595-602, 2013.
11. Jia Y, Zhang Y, Qiao C, et al: IGF-1R and ErbB3/HER3 contribute to enhanced proliferation and carcinogenesis in trastuzumab-resistant ovarian cancer model. Biochem Biophys Res Commun 436: 740-745, 2013.
12. Sharmila G, Bhat FA, Arunkumar R, et al: Chemopreventive effect of quercetin, a natural dietary flavonoid on prostate cancer in in vivo model. Clin Nutr: Sep 3, 2013 (Epub ahead of print). doi: 10.1016/j.clnu.2013.08.011.
13. Wilson S and Chia SK: IGF-1R inhibition: right direction, wrong pathway? Lancet Oncol 14: 182-183, 2013.
14. Zhao X, Dou W, He L, et al: MicroRNA-7 functions as an anti-metastatic microRNA in gastric cancer by targeting insulin-like growth factor-1 receptor. Oncogene 32: 1363-1372, 2013.
15. Werner H and Bruchim I: The insulin-like growth factor-I receptor as an oncogene. Arch Physiol Biochem 115: 58-71, 2009.
16. Wei Z, Hurtt R, Gu T, et al: GRK2 negatively regulates IGF-1R signaling pathway and cyclins' expression in HepG2 cells. J Cell Physiol 228: 1897-1901, 2013.
17. Fürstenberger G, Senn E, Morant R, Bolliger B and Senn HJ: Serum levels of IGF-1 and IGFBP-3 during adjuvant chemotherapy for primary breast cancer. Breast 15: 64-68, 2006. (Pubitemid 43210551)
18. Ozkan EE: Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review. Mol Cell Endocrinol 344: 1-24, 2011.
19. Thariat J, Bensadoun RJ, Etienne-Grimaldi MC, et al: Contrasted outcomes to gefitinib on tumoral IGF1R expression in head and neck cancer patients receiving postoperative chemoradiation (GORTEC trial 2004-02). Clin Cancer Res 18: 5123-5133, 2012.
20. Peled N, Wynes MW, Ikeda N, et al: Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer. Cell Oncol 36: 277-288, 2013.
21. Jones HE, Gee JM, Barrow D, et al: Inhibition of insulin receptor isoform-A signalling restores sensitivity to gefitinib in previously de novo resistant colon cancer cells. Br J Cancer 95: 172-180, 2006. (Pubitemid 44050916)
22. Imsumran A, Adachi Y, Yamamoto H, et al : Insulin-like growth factor-I receptor as a marker for prognosis and a therapeutic target in human esophageal squamous cell carcinoma. Carcinogenesis 28: 947-956, 2007. (Pubitemid 47072177)
23. Liu YC, Leu CM, Wong FH, et al: Autocrine stimulation by insulin-like growth factor I is involved in the growth, tumorigenicity and chemoresistance of human esophageal carcinoma cells. J Biomed Sci 9: 665-674, 2002.
24. Dhillon AS, Hagan S, Rath O and Kolch W: MAP kinase signalling pathways in cancer. Oncogene 26: 3279-3290, 2007. (Pubitemid 46763021)
25. Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell 144: 646-674, 2011.
26. Negi A, Ramarao P and Kumar R: Recent advancements in small molecule inhibitors of insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase as anticancer agents. Mini Rev Med Chem 13: 653-681, 2013.
27. Soria JC, Massard C, Lazar V, et al: A dose finding, safety and pharmacokinetic study of AVE1642, an anti-insulin-like growth factor-1 receptor (IGF-1R/CD221) monoclonal antibody, administered as a single agent and in combination with docetaxel in patients with advanced solid tumours. Eur J Cancer 49: 1799-1807, 2013.
28. Ioannou N, Seddon AM, Dalgleish A, Mackintosh D and Modjtahedi H: Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells. BMC Cancer 13: 41, 2013.
29. Haluska P, Carboni JM, Loegering DA, et al: In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. Cancer Res 66: 362-371, 2006. (Pubitemid 43166043)
30. Ucar DA, Cox A, He DH, et al: A novel small molecule inhibitor of FAK and IGF-1R protein interactions decreases growth of human esophageal carcinoma. Anticancer Agents Med Chem 11: 629-637, 2011.